Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, single institution, Phase 1 study of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab for adolescent and young adult participants with relapsed or refractory T-ALL or T-LBL
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 12 do 30 lat
- •Diagnoza potwierdzonych nawrotowych lub opornych na leczenie białaczek lub chłoniaków T-komórkowych
- •Masa ciała co najmniej 40 kg
- •Wystarczająca funkcja serca (frakcja wyrzutu co najmniej 40%)
- •Wystarczająca funkcja wątroby i nerek
- •Możliwość przyjmowania leków doustnie lub dożylnie
- •Brak zakaźnego HCV (hepatitis C), lub jeśli leczone - brak wirusa we krwi
- •Jeśli pacjent ma HBV (zapalenie wątroby B) - wirus musi być suppressowany lekami
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Maximum age
- 30 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
UT MD Anderson
Houston, United States
Trial contact
Miriam B Garcia, DO
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.